Subscribe To
PEAR / Pear Therapeutics' Digital Therapeutic For Insomnia Shows Meaningful Reductions In Severity Through 6 Months
Content Topics
PEAR
Therapeutics
Digital
Therapeutic
Insomnia
Shows
Therapeutics
Meaningful
Reductions
Severity
Through
Months
Stock
PEAR News
By InvestorPlace
April 14, 2023
Why Is Pear Therapeutics (PEAR) Stock Down 26% Today?
Pear Therapeutics (NASDAQ: PEAR ) stock is falling on Friday after the company's recent bankruptcy filing continues to weigh on its shares. Pear Thera more_horizontal
By InvestorPlace
March 21, 2023
Why Is Pear Therapeutics (PEAR) Stock Up 21% Today?
Pear Therapeutics (NASDAQ: PEAR ) stock is climbing higher on Tuesday despite the company's plans to explore strategic alternatives. That news was fir more_horizontal
By Zacks Investment Research
January 19, 2023
Pear Therapeutics, Inc. (PEAR) Loses -17.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Pear Therapeutics, Inc. (PEAR) as it is technically in oversold territory now. In addition to this more_horizontal
By Seeking Alpha
November 14, 2022
Pear Therapeutics Inc. (PEAR) Q3 2022 Earnings Call Transcript
Pear Therapeutics Inc. (NASDAQ:PEAR ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Meara Murphy – Senior Direc more_horizontal
By Seeking Alpha
May 17, 2022
Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q1 2022 Results - Earnings Call Transcript
Pear Therapeutics, Inc. (NASDAQ:PEAR ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Meara Murphy - Senior Director of more_horizontal
By Seeking Alpha
March 28, 2022
Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q4 2021 Results - Earnings Call Transcript
Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q4 2021 Results - Earnings Call Transcript more_horizontal
By Benzinga
March 15, 2022
Pear Therapeutics' Digital Therapeutic For Insomnia Shows Meaningful Reductions In Severity Through 6 Months
Pear Therapeutics Inc (NASDAQ: PEAR) announced data that further underscore the effectiveness of Somryst for chronic insomnia at the World Sleep 2022 more_horizontal